# CMPS catalysts: COMPASS Pathways plc PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/cmps/catalysts

> COMPASS Pathways plc (CMPS) has 2 upcoming catalysts. The next is the comp360 psilocybin primary completion, November 2028.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | COMPASS Pathways plc |
| Ticker | CMPS (Nasdaq) |
| SEC CIK | 1816590 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/cmps |

## Cash runway

Cash $444.0M as of 2026-09-30; quarterly burn $50.8M; about 26.2 months of runway at that rate (XBRL company facts, accession 0001816590-26-000076).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Nov 2022 | [COMP360 topline data readout](https://sec-api.dev/pdufa/comp360) | CMPS |  | completed, positive | "We announced positive top-line results from this trial in November 2021, the results of which were published in the New England Journal of Medicine in November 2022." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1816590/000162828025008412/cmps-20241231.htm)) |
| February 27, 2025 | [COMPASS Pathways plc earnings report](https://sec-api.dev/companies/cmps/catalysts) | CMPS |  | completed | "Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the fourth quarter and full year 2024 and provided an update on recent progress across its business." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1816590/000162828025008414/q42024pressrelease.htm)) |
| Q2 2025 | [COMP005 topline data readout](https://sec-api.dev/pdufa/comp005) | CMPS | treatment resistant depression | scheduled | "We are nearing completion of enrollment in our first pivotal study in TRD, COMP005, and expect to report top-line 6-week data in the second quarter of 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1816590/000162828025008412/cmps-20241231.htm)) |
| May 8, 2025 | [COMPASS Pathways plc earnings report](https://sec-api.dev/companies/cmps/catalysts) | CMPS |  | completed | "Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1816590/000162828025023427/q12025pressrelease.htm)) |
| May 28, 2025 | [Psilocybin primary completion](https://sec-api.dev/pdufa/psilocybin) | CMPS | Treatment Resistant Depression | completed | "NCT05624268 (Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-28 (ACTUAL); Lead Sponsor COMPASS Pathways." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05624268)) |
| Jun 2025 | [COMP006 topline data readout](https://sec-api.dev/pdufa/comp006) | CMPS |  | scheduled | "We expect to report top-line 6 week primary endpoint results in late June 2025 and then the 26-week data once all participants in the COMP006 trial have completed Part A of the COMP006 trial." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1816590/000162828025023426/cmps-20250331.htm)) |
| July 31, 2025 | [COMPASS Pathways plc earnings report](https://sec-api.dev/companies/cmps/catalysts) | CMPS |  | completed | "Compass Pathways Announces Second Quarter 2025 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1816590/000181659025000103/q22025pressrelease.htm)) |
| September 2025 | [Psilocybin primary completion](https://sec-api.dev/pdufa/psilocybin) | CMPS | Major Depressive Disorder | delayed | "NCT05733546 (A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-09 (ESTIMATED); Lead Sponsor COMPASS Pathways." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05733546)) |
| November 4, 2025 | [COMPASS Pathways plc earnings report](https://sec-api.dev/companies/cmps/catalysts) | CMPS |  | completed | "Compass Pathways Announces Third Quarter 2025 Financial Results and Business Highlights Including Acceleration of Commercial Launch Plans by 9-12 Months" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1816590/000181659025000149/q32025pressrelease.htm)) |
| November 13, 2025 | [Psilocybin primary completion](https://sec-api.dev/pdufa/psilocybin) | CMPS | Treatment Resistant Depression | completed | "NCT05711940 (Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-11-13 (ACTUAL); Lead Sponsor COMPASS Pathways." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05711940)) |
| March 24, 2026 | [COMPASS Pathways plc earnings report](https://sec-api.dev/companies/cmps/catalysts) | CMPS |  | completed | "Compass Pathways Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000021/q42025pressrelease.htm)) |
| May 13, 2026 | [COMPASS Pathways plc earnings report](https://sec-api.dev/companies/cmps/catalysts) | CMPS |  | completed | "Compass Pathways Announces First Quarter 2026 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000043/q12026pressrelease.htm)) |
| Q3 2026 | [COMP006 NDA/BLA submission](https://sec-api.dev/pdufa/comp006) | CMPS |  | scheduled | "•26-week (Part B) data from COMP006 in early Q3 2026 is expected to be the final dataset for NDA submission" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000021/q42025pressrelease.htm)) |
| 2H 2026 | [COMP006 topline data readout](https://sec-api.dev/pdufa/comp006) | CMPS |  | scheduled | "We expect to report top-line data by the second half of 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1816590/000162828025023426/cmps-20250331.htm)) |
| August 5, 2026 | [COMPASS Pathways plc earnings report](https://sec-api.dev/companies/cmps/catalysts) | CMPS |  | completed | "Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000059/q22026pressrelease.htm)) |
| Q4 2026 | [COMPASS Pathways plc topline data readout](https://sec-api.dev/companies/cmps/catalysts) | CMPS |  | scheduled | "550 adult patients, with the first Phase 3 trial expected to report top-line data in the fourth quarter of 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000076/cmps-20260930.htm)) |
| November 3, 2026 | [COMPASS Pathways plc earnings report](https://sec-api.dev/companies/cmps/catalysts) | CMPS |  | completed | "Compass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000078/q32026pressrelease.htm)) |
| November 2028 | [Comp360 psilocybin primary completion](https://sec-api.dev/pdufa/comp360-psilocybin) | CMPS | PTSD - Post Traumatic Stress Disorder; PTSD; PTSD Symptoms | scheduled | "NCT07570654 (Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-11 (ESTIMATED); Lead Sponsor COMPASS Pathways." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07570654)) |
| Nov 2028 to Feb 2029 | [Comp360 psilocybin topline data readout](https://sec-api.dev/pdufa/comp360-psilocybin) | CMPS | PTSD - Post Traumatic Stress Disorder; PTSD; PTSD Symptoms | scheduled | "NCT07570654 (Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-11 (ESTIMATED); Lead Sponsor COMPASS Pathways." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07570654)) |

## Drugs

- [COMP005](https://sec-api.dev/pdufa/comp005): treatment resistant depression
- [COMP006](https://sec-api.dev/pdufa/comp006): 
- [COMP360](https://sec-api.dev/pdufa/comp360): 
- [Comp360 psilocybin](https://sec-api.dev/pdufa/comp360-psilocybin): PTSD - Post Traumatic Stress Disorder
- [Psilocybin](https://sec-api.dev/pdufa/psilocybin): adjustment disorder in patients with cancer, Treatment Resistant Depression, Major Depressive Disorder

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/cmps/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "CMPS catalysts: COMPASS Pathways plc PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/cmps/catalysts

```bibtex
@misc{secapidev_companies_cmps_catalysts_20261116,
  title        = {CMPS catalysts: COMPASS Pathways plc PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/cmps/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_cmps_catalysts_20261116","title":"CMPS catalysts: COMPASS Pathways plc PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/cmps/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
